Common TitleENDURANCE-3
Official Title Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Phase Phase III
ClinicalTrials.gov NCT02640157
Treatments
Glecaprevir-Pibrentasvir
Glecaprevir-Pibrentasvir
Tradename:MavyretOther Names:GLE-PIBClass:FDA-ApprovedFunding
IndustryAbbVie